Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations
Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term
The Healthcare M&A Wave
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
Is Amneal a Buy Before Rytary Generic Erosion?
What's Driving Amneal's 2026 Growth Outlook?
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- GF Value $7.57 vs Price $12.21
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Amneal Reports First Quarter 2026 Financial Results
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
Amneal 2026-2027 Upside From Biosimilars Scale
AMRX Growth Drivers: Generics, Biosimilars, and Crexont
AMRX Valuation: What 1.69x Sales Means for Investors
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential
A Look at Amneal Pharmaceuticals Inc (AMRX) After 4.7% Decline -- GF Value $6.98 vs Price $13.26
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Significant Decrease in Short Interest